口服小分子研发商REVIER Therapeutics获得600万欧元种子轮融资-动脉网

REVIER Therapeutics launches with €6 million seed financing

D-Pharm 等信源发布 2026-08-27 15:57



可切换为仅中文







Revier Therapeutics announced the closing of a EUR 6 million

Revier Therapeutics 宣布完成 600 万欧元的融资交割

seed financing

种子轮融资

and the launch of its operations. The Company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of

并启动其运营。本公司已建立首个选择性靶向IIa类组蛋白去乙酰化酶（HDACs）以用于治疗的治疗方法。

cardiometabolic diseases

心脏代谢疾病

. The financing was led by the KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg.

本轮融资由KHAN技术转移基金二期领投，High-Tech Gründerfonds（HTGF）、VORNvc以及通过Revier Invest Heidelberg参与的私人投资者跟投。

The Revier Therapeutics Team

Revier 治疗团队

Revier Therapeutics

Funding from the round will support development of Revier’s preclinical cardiometabolic pipeline, including its lead program in heart failure with preserved ejection fraction (HFpEF) and its second program in atherosclerotic cardiovascular disease (ASCVD) as well as the build out of its operational, scientific and clinical functions..

本轮融资将支持Revier公司临床前心血管代谢产品管线的开发，包括其针对射血分数保留的心力衰竭（HFpEF）的首要项目以及针对动脉粥样硬化性心血管疾病（ASCVD）的第二个项目，同时还将用于建设其运营、科学和临床职能体系。

“Despite significant progress in cardiovascular medicine, millions of patients with HFpEF and ASCVD still to date face limited targeted treatment options,” said Prof. Eva van Rooij, PhD, co-founder and Chief Executive Officer of Revier Therapeutics. “We believe the next generation of cardiometabolic medicines needs to address the underlying disease-driving biology to deliver impactful and long-term solutions for patients.

“尽管心血管医学取得了显著进展，但迄今为止，数百万射血分数保留的心力衰竭（HFpEF）合并动脉粥样硬化性心血管疾病（ASCVD）患者仍面临有限的靶向治疗选择，”Revier Therapeutics 联合创始人兼首席执行官 Eva van Rooij 博士表示。“我们认为，下一代心脏代谢疾病药物需要针对驱动疾病的根本生物学机制，为患者提供具有深远影响且长期的解决方案。”

Our mission is to translate the scientific potential of class IIa HDAC inhibition into a pipeline of novel therapies and rapidly advance our lead programs toward the clinic to create long-term value for both patients and the broader healthcare ecosystem.”.

我们的使命是将IIa类组蛋白去乙酰化酶（HDAC）抑制的科学潜力转化为一系列新型疗法，并快速推进我们的领先项目进入临床应用，从而为患者和更广泛的医疗生态系统创造长期价值。

TNO spin-off AIKON Health secures €1.2 million seed round to advance remote heart failure monitoring

TNO衍生公司AIKON Health完成120万欧元种子轮融资，以推进远程心力衰竭监测技术

Shifting care from hospital to home

将护理从医院转移到家庭

Read news

阅读新闻

HDACs are enzymes that play a functional role in a variety of severe diseases. Pioneering discoveries, including foundational work at Heidelberg University led by Prof. Johannes Backs, MD, Revier’s scientific founder, defined the specific impact of class IIa HDACs on cardiometabolic diseases.

组蛋白去乙酰化酶（HDACs）是一类在多种严重疾病中发挥功能作用的酶。包括由Revier科学创始人、医学博士Johannes Backs教授在海德堡大学领导的基础性研究在内的开创性发现，阐明了IIa类HDACs对心脏代谢疾病的具体影响。

Prof. Johannes Backs, MD, scientific founder of Revier Therapeutics added: “While first generation HDAC inhibitors broadly targeted multiple HDAC classes resulting in dose-limiting side effects, Revier’s first-in-class small molecules selectively target class IIa HDACs. These compounds specifically inhibit the disease-driving enzymatic activity while preserving the essential functions of class IIa HDACs and canonical class I HDACs.

Johannes Backs 医学博士、Revier Therapeutics 的科学创始人补充道：“虽然第一代 HDAC 抑制剂广泛靶向多种 HDAC 类别，导致出现剂量限制性副作用，但 Revier 的首创小分子药物选择性地靶向 IIa 类 HDAC。这些化合物特异性地抑制驱动疾病的酶活性，同时保留 IIa 类 HDAC 和经典 I 类 HDAC 的基本功能。”

This precise mode of action is designed to be therapeutically effective while maintaining a beneficial safety profile.”.

这种精确的作用机制旨在保持良好安全性的同时发挥治疗效力。

“Revier’s differentiated class IIa HDAC strategy in cardiometabolic disease has the potential to unlock the therapeutic promise of HDAC biology while overcoming limitations associated with earlier class I HDAC approaches,” said Michael Hamacher, PhD, Managing Partner and CFO at KHAN Technology Transfer Fund II.

“Revier在 cardiometabolic 疾病中采用的差异化IIa类HDAC策略，有望释放HDAC生物学机制的治疗潜力，同时克服早期I类HDAC方法相关的局限性。”KHAN技术转移基金II的管理合伙人兼首席财务官Michael Hamacher博士表示。

“Combined with an exceptional leadership team and deep scientific expertise, the company has a unique opportunity to deliver disease-modifying medicines and reshape the standard of care by providing durable benefit for patients with HFpEF, ASCVD and related cardiometabolic disorders.”.

“凭借卓越的领导团队和深厚的科学专业知识，该公司拥有独特的机会，通过为射血分数保留的心力衰竭（HFpEF）、动脉粥样硬化性心血管疾病（ASCVD）及相关心脏代谢性疾病患者提供持久获益，从而提供疾病修饰疗法并重塑治疗标准。”

The Company’s seed financing includes support from a coalition of regional stakeholders and investors led by the business developer Daniel Stern (founder of Revier Invest Heidelberg), underscoring the strategic importance of biotechnology for both the local community and the state of Baden‑Württemberg..

该公司的种子轮融资获得了由商业开发者丹尼尔·斯特恩（Revier Invest Heidelberg 创始人）领衔的区域利益相关者和投资者联盟的支持，这凸显了生物技术对当地社区和巴登-符腾堡州的战略重要性。

In conjunction with the company launch, Revier announced its leadership team, bringing together renowned experts in cardiovascular science, drug discovery, clinical development and biotechnology.

伴随公司成立，Revier宣布了其领导团队，汇聚了心血管科学、药物发现、临床开发和生物技术领域的知名专家。

Key leadership includes:

核心领导层包括：

Prof. Johannes Backs, MD, Scientific Founder – Director of the Institute of Experimental Cardiology at Heidelberg University, Director of the Helmholtz Institute for Translational AngioCardioScience (HI-TAC), and Professor of the German Center for Cardiovascular Research (DZHK).

约翰内斯·巴克斯教授，医学博士，科学创始人——海德堡大学实验心脏病学研究所所长，亥姆霍兹转化血管心血管科学研究所（HI-TAC）所长，德国心血管研究中心（DZHK）教授。

Prof. Eva van Rooij, PhD, Chief Executive Officer – A serial biotechnology entrepreneur and Professor of Molecular Cardiology at University Medical Center Utrecht, with extensive expertise in cardiovascular translational research.

埃娃·范罗伊博士，首席执行官——连续生物技术创业者，乌得勒支大学医学中心分子心脏病学教授，在心血管转化研究领域拥有深厚的专业造诣。

Mike Nolan, PhD, Chief Technology Officer – A corresponding author of the initial publications describing selective class IIa HDAC inhibitors with 20+ years of industry experience in drug discovery, innovative research platforms, and company creation.

迈克·诺兰博士，首席技术官——描述选择性IIa类HDAC抑制剂的初始出版物的通讯作者之一，拥有超过20年的药物发现、创新研究平台及公司创建的行业经验。

Matthias Dewenter, MD, Chief Scientific Officer – An expert in translational cardiovascular research and the preclinical development of novel therapeutic approaches for heart failure and cardiometabolic disease.

马蒂亚斯·德文特（Matthias Dewenter）医学博士，首席科学官——转化心血管研究以及心力衰竭和心脏代谢疾病新型治疗方法的临床前开发专家。

Prof. Norbert Frey, MD, Chief Medical Officer – Director of the Department of Cardiology, Angiology and Pneumology at Heidelberg University Hospital, translational researcher, and clinical trial leader with decades of expertise advancing new treatments for cardiovascular disease.

诺伯特·弗雷教授，医学博士，首席医疗官——海德堡大学医院心脏病学、血管病学和肺病学系主任，转化研究者，拥有数十年推动心血管疾病新疗法的临床试验领导经验。

https://www.bionity.com/en/news/1189671/revier-therapeutics-launches-with-6-million-seed-financing.html

Artificial intelligence recognizes heart disease by the sound of the voice

人工智能通过语音识别心脏病

AI from a Berlin start-up is used for this purpose

为此目的，使用了来自柏林一家初创公司的人工智能技术

Read news

阅读新闻